Literature DB >> 31580454

Influence of prior antibiotic use on risk of rheumatoid arthritis: case control study in general practice.

David Armstrong1, Alex Dregan2, Mark Ashworth1, Patrick White1, Chris McGee3,4, Simon de Lusignan3,4.   

Abstract

OBJECTIVES: To test the hypothesis that prior antibiotics influences the risk of developing RA.
METHODS: A case-control study was conducted over 15 years using the UK's Royal College of General Practitioners Research and Surveillance Centre database. The frequency and type of antibiotic prescription for patients who subsequently developed RA were compared with antibiotic prescriptions in a control group of patients who remained free of RA. Cases, defined as patients with a new diagnosis of RA made between 2006 and 2018, were matched with up to four RA-free controls on practice, age, gender and date of diagnosis. Exposure was measured by the number and type of prescriptions for antibiotics prior to the RA diagnosis or to the index date in controls.
RESULTS: A total of 8482 patients with a new diagnosis of RA between 2006 and 2018 were compared with 22 661 controls. There was a higher likelihood of an RA diagnosis after antibiotic prescriptions within 1 year, 5 years and ever with a strong dose-response. Patients receiving >10 antibiotics in a 5 year period were more than twice as likely to receive an RA diagnosis as controls [adjusted odds ratio 2.65 (CI 2.40, 2.93)].
CONCLUSION: Exposure to antibiotics prior to the diagnosis was a significant risk factor for RA. This could reflect an immunological response to a compromised microbiome. Alternatively, patients with pre-symptomatic or early undiagnosed RA may have been more likely to present to their general practitioner with infections due to an unrecognized effect of RA.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  RA; epidemiology; infection

Mesh:

Substances:

Year:  2020        PMID: 31580454     DOI: 10.1093/rheumatology/kez452

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

1.  Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study.

Authors:  Jinqiu Yuan; Changhua Zhang; Jeffrey A Sparks; Susan Malspeis; Kelvin Kam-Fai Tsoi; Jean H Kim; Benjamin A Fisher; Fang Gao; Tim Sumerlin; Yan Liu; Yuxing Liu; Yihang Pan; Yulong He; Joseph J Y Sung
Journal:  Aliment Pharmacol Ther       Date:  2020-06-29       Impact factor: 8.171

Review 2.  Gut microbiome and autoimmune disorders.

Authors:  Walaa Abdelaty Shaheen; Mohammed Nabil Quraishi; Tariq H Iqbal
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

3.  Timing of sinusitis and other respiratory tract diseases and risk of rheumatoid arthritis.

Authors:  Vanessa L Kronzer; Weixing Huang; Cynthia S Crowson; John M DavisIII; Robert Vassallo; Tracy J Doyle; Elena Losina; Jeffrey A Sparks
Journal:  Semin Arthritis Rheum       Date:  2021-12-31       Impact factor: 5.532

Review 4.  Etiologies of Rheumatoid Arthritis: Update on Mucosal, Genetic, and Cellular Pathogenesis.

Authors:  Vanessa L Kronzer; John M Davis
Journal:  Curr Rheumatol Rep       Date:  2021-03-01       Impact factor: 4.592

5.  Outpatient Use of Antimicrobials in Patients With Rheumatoid Arthritis Before and After Treatment With Tumor Necrosis Factor Inhibitors: A Nationwide Retrospective Cohort Study.

Authors:  Aron H Bjornsson; Olafur Palsson; Mar Kristjansson; Petur S Gunnarsson; Gerdur Grondal; Bjorn Gudbjornsson; Thorvardur J Love
Journal:  ACR Open Rheumatol       Date:  2021-11-29

6.  What is the optimal strategy for managing primary care patients with an uncomplicated acute sore throat? Comparing the consequences of nine different strategies using a compilation of previous studies.

Authors:  Ronny Gunnarsson; Ulrich Orda; Bradley Elliott; Clare Heal; Chris Del Mar
Journal:  BMJ Open       Date:  2022-04-29       Impact factor: 3.006

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.